Date  |
|
| Jul 7, 2021 |
CEL-SCI Corporation Issues Letter to Shareholders |
| Jul 2, 2021 |
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available |
| Jun 30, 2021 |
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021 |
| Jun 28, 2021 |
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study |
| Jun 25, 2021 |
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting |
| Jun 11, 2021 |
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering |
| Jun 8, 2021 |
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million |
| Jun 8, 2021 |
CEL-SCI Announces Bought Deal Offering |
| May 18, 2021 |
CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results |
| Feb 16, 2021 |
CEL-SCI Corporation Reports First Quarter Fiscal 2021 Financial Results |